PT - JOURNAL ARTICLE AU - Ganesh, Aravind AU - Stang, Jillian M. AU - McAlister, Finlay A. AU - Shlakhter, Oleksandr AU - Holodinsky, Jessalyn K. AU - Mann, Balraj AU - Hill, Michael D. AU - Smith, Eric E. TI - Changes in ischemic stroke presentations and associated workflow during the first wave of the COVID-19 pandemic: A population study in Alberta, Canada AID - 10.1101/2021.10.04.21264529 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.04.21264529 4099 - http://medrxiv.org/content/early/2021/10/07/2021.10.04.21264529.short 4100 - http://medrxiv.org/content/early/2021/10/07/2021.10.04.21264529.full AB - Background Pandemics may promote hospital avoidance among patients with emergencies, and added precautions may exacerbate treatment delays. There is a paucity of population-based data on these phenomena for stroke. We examined the effect of the COVID-19 pandemic on the presentation and treatment of ischemic stroke in an entire population.Methods We used linked provincial administrative data and data from the Quality Improvement and Clinical Research Alberta Stroke Program – a registry capturing stroke-related data on the entire population of Alberta(4.3 million)– to identify all patients presenting with stroke in the pre-pandemic(1-January-2016 to 27-February-2020, n=19,531) and pandemic(28-February-2020 to 30-August-2020, n=2,255) periods. We examined changes in thrombolysis and endovascular therapy(EVT) rates, workflow, and in-hospital outcomes.Results Hospitalizations/presentations for ischemic stroke dropped (weekly adjusted-incidence-rate-ratio[aIRR]:0.48, 95%CI:0.46-0.50, adjusted for age, sex, comorbidities, pre-admission care needs), as did population-level incidence of thrombolysis(aIRR:0.49,0.44-0.56) or EVT(aIRR:0.59,0.49-0.69). However, the proportions of presenting patients receiving acute therapies did not decline (e.g. thrombolysis:11.7% pre-pandemic vs 13.1% during-pandemic, aOR:1.02,0.75-1.38). Onset-to-door times were prolonged; EVT recipients experienced longer door-to-reperfusion times (median door-to-reperfusion:110-minutes, IQR:77-156 pre-pandemic vs 132.5-minutes, 99-179 during-pandemic; adjusted-coefficient:18.7-minutes, 95%CI:1.45-36.0). Hospitalizations were shorter but stroke severity and in-hospital mortality did not differ.Interpretation The first COVID-19 wave was associated with a halving of presentations and acute therapy utilization for ischemic stroke at a population level, and greater pre-hospital and in-hospital treatment delays. Our data can inform public health messaging and stroke care in current and future waves. Messaging should encourage attendance for emergencies and stroke systems should re-examine “code stroke” protocols to mitigate inefficiencies.Competing Interest StatementDr. GANESH reports membership in the editorial boards of Neurology, Stroke, and Neurology Clinical Practice; consulting fees from MD Analytics, Atheneum, CTC Communications Corporation, MyMedicalPanel, and Creative Research Designs; research support from the University of Calgary, Sunnybrook Research Institute (INOVAIT program), Alberta Innovates, Campus Alberta Neuroscience, the Canadian Cardiovascular Society, and the Canadian Institutes of Health Research (CIHR); stock/stock options from SnapDx, TheRounds.ca, and Advanced Health Analytics (AHA Health Ltd); and has a provisional patent application (US 63/024,239) for a system for pre-hospital patient monitoring/assessment and delivery of remote ischemic conditioning or other cuff-based therapies. Ms. STANG reports no disclosures. Dr. MCALISTER holds the Alberta Health Services Chair in Cardiovascular Outcomes Research. Dr. SHLAKHTER reports no disclosures. Ms. MANN reports no disclosures. Dr. HOLODINSKY reports funding from the Canadian Institutes of Health Research. Dr. HILL reports a patent to US Patent office Number: 62/086,077 issued and licensed; owns stock in Pure Web Incorporated, a company that makes, among other products, medical imaging software; is a director of the Canadian Federation of Neurological Sciences, the Canadian Stroke Consortium (not-for-profit groups), and Circle Neurovascular Inc., and has received grant support from Alberta Innovates Health Solutions, CIHR, Heart & Stroke Foundation of Canada, and National Institutes of Neurological Disorders and Stroke. Dr. SMITH reports grant funding from the Canadian Institutes of Health Research, Brain Canada, and the Weston Brain Institute; consulting fees from Bayer, Biogen, and Javelin; royalties from UpToDate; and payment from the American Heart Association for work as Associate Editor of Stroke.Funding StatementThe study was funded by the Canadian Cardiovascular Society (CCS) through the COVID-19 Challenge for Canada Initiative (CCS-C3I).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Calgary Conjoint Health Research Ethics Board.(REB20-0769). No informed consent was required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.